Who founded Zenas Biopharma?

Zenas Biopharma was founded by LEON O. MOULDER, JR., Lonnie Moulder in 2019.

Who are Zenas Biopharma's investors?

Zenas Biopharma's investors include Delos Capital, Longitude Capital, New Enterprise Associates (NEA), Norwest Venture Partners, Quan Capital, SR One Capital Management, Vivo Capital, Agent Capital.

How much funding has Zenas Biopharma raised?

Zenas Biopharma has disclosed $384M raised across 2 rounds.

Where is Zenas Biopharma headquartered?

Zenas Biopharma is headquartered in Waltham, US.

Zenas Biopharma

NASDAQ: ZBIO

Waltham, US · Founded 2019 · Delaware corporation · 8 known investors

zenasbio.com ↗

Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor. Its products are aimed at patients with multiple autoimmune conditions with unmet medical needs.

BiotechHealthtech

Founders & leadership

Zenas Biopharma was founded in 2019 by LEON O. MOULDER, JR. and Lonnie Moulder.

LEON O. MOULDER, JR.Co-founder

Lonnie MoulderFounder, CEO & Chairman

JOSEPH FARMERExecutive

HUA MUExecutive

Board

PATRICK GERALD ENRIGHTBoard directorManaging Director at Longitude Capital

HONGBO LUBoard director

TOMAS KISELAKBoard director

JOHN JACOB ORLOFFBoard directorVenture Partner at Agent Capital

JAMES PATRICK BOYLANBoard directorChief Executive Officer at Enavate Sciences

MARIETTA WUBoard directorManaging Director at Quan Capital

Investors · 8

Delos CapitalCambridge

Longitude CapitalMenlo Park · $10M – $30M

New Enterprise Associates (NEA)Menlo Park · $200K – $40M

Norwest Venture PartnersMenlo Park · $10M – $30M

Quan CapitalShanghai

SR One Capital ManagementRedwood City

Vivo CapitalPalo Alto · $10M – $50M

Agent Capitalreported · 2 sourcesWalthamvia John Orloff · board

Reported raises · per SEC filings

Form D private placements

$384M disclosed across 2 rounds · 2022–2024

▶$200.1MraisedMay 2024 · 26 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

PATRICK GERALD ENRIGHTDirector
TOMAS KISELAKDirector
PATRICIA ALLENDirector
JOSEPH FARMERExecutive Officer
LEON O. MOULDER, JR.Executive Officer, Director
JAKE NUNNDirector
TIM XIAODirector
JENNIFER FOXExecutive Officer
JAMES PATRICK BOYLANDirector
TANYA Z. FISCHERExecutive Officer
JOHN JACOB ORLOFFDirector
HONGBO LUDirector

Offering amount: $200.1M
Amount sold: $200.1M
First sale: May 2024
Incorporated: Corporation, Delaware, 2023
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$183.9MraisedNov 2022 · 17 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

JOSEPH FARMERExecutive Officer
PATRICK GERALD ENRIGHTDirector
HONGBO LUDirector
TOMAS KISELAKDirector
LEON O. MOULDER, JR.Director
JOHN JACOB ORLOFFDirector
JAMES PATRICK BOYLANDirector
HUA MUExecutive Officer, Director
MARIETTA WUDirector

Offering amount: $183.9M
Amount sold: $183.9M
First sale: Nov 2022
Incorporated: Other, Cayman Islands, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap

Robinhood26 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.

Seeking Alpha23 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.

Day One Biopharmaceuticals19 shared keywordsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.

Bioworld19 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Zenas Biopharma for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Zenas Biopharma do?: Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor. Its products are aimed at patients with multiple autoimmune conditions with unmet medical needs.
Who founded Zenas Biopharma?: Zenas Biopharma was founded by LEON O. MOULDER, JR., Lonnie Moulder in 2019.
Who are Zenas Biopharma's investors?: Zenas Biopharma's investors include Delos Capital, Longitude Capital, New Enterprise Associates (NEA), Norwest Venture Partners, Quan Capital, SR One Capital Management, Vivo Capital, Agent Capital.
How much funding has Zenas Biopharma raised?: Zenas Biopharma has disclosed $384M raised across 2 rounds.
Where is Zenas Biopharma headquartered?: Zenas Biopharma is headquartered in Waltham, US.